Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jessica Frankum

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Molecular Cancer Therapeutics|June 17, 2015
Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast CancerYeon-Jin Kwon, Kevin Petrie, Boris A Leibovitch, et al.
Cancer Research|October 18, 2017
ATR Is a Therapeutic Target in Synovial SarcomaSamuel E Jones, Emmy D G Fleuren, Jessica Frankum, et al.
Cancer Discovery|March 15, 2015
Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast CancersJohnathan Watkins, Daniel Weekes, Vandna Shah, et al.
Cell Reports|May 17, 2018
The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient CellsMarco Barazas, Stefano Annunziato, Stephen J Pettitt, et al.
Nature Communications|May 12, 2018
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistanceStephen J Pettitt, Dragomir B Krastev, Inger Brandsma, et al.
Cell Reports|March 8, 2016
Large-Scale Profiling of Kinase Dependencies in Cancer Cell LinesJames Campbell, Colm J Ryan, Rachel Brough, et al.
The Journal of Pathology|January 8, 2014
Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breastRachael Natrajan, Paul M Wilkerson, Caterina Marchiò, et al.
Oncogene|February 12, 2025
PPP2R1A mutations cause ATR inhibitor sensitivity in ovarian clear cell carcinomaJames Stewart, Dragomir B Krastev, Rachel Brough, et al.
Cancer Discovery|April 4, 2018
E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast CancerIlirjana Bajrami, Rebecca Marlow, Marieke van de Ven, et al.
Nature|July 20, 2018
The shieldin complex mediates 53BP1-dependent DNA repairSylvie M Noordermeer, Salomé Adam, Dheva Setiaputra, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Molecular Cancer Therapeutics|June 17, 2015
Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast CancerYeon-Jin Kwon, Kevin Petrie, Boris A Leibovitch, et al.
Cancer Research|October 18, 2017
ATR Is a Therapeutic Target in Synovial SarcomaSamuel E Jones, Emmy D G Fleuren, Jessica Frankum, et al.
Cancer Discovery|March 15, 2015
Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast CancersJohnathan Watkins, Daniel Weekes, Vandna Shah, et al.
Cell Reports|May 17, 2018
The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient CellsMarco Barazas, Stefano Annunziato, Stephen J Pettitt, et al.
Nature Communications|May 12, 2018
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistanceStephen J Pettitt, Dragomir B Krastev, Inger Brandsma, et al.
Cell Reports|March 8, 2016
Large-Scale Profiling of Kinase Dependencies in Cancer Cell LinesJames Campbell, Colm J Ryan, Rachel Brough, et al.
The Journal of Pathology|January 8, 2014
Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breastRachael Natrajan, Paul M Wilkerson, Caterina Marchiò, et al.
Oncogene|February 12, 2025
PPP2R1A mutations cause ATR inhibitor sensitivity in ovarian clear cell carcinomaJames Stewart, Dragomir B Krastev, Rachel Brough, et al.
Cancer Discovery|April 4, 2018
E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast CancerIlirjana Bajrami, Rebecca Marlow, Marieke van de Ven, et al.
Nature|July 20, 2018
The shieldin complex mediates 53BP1-dependent DNA repairSylvie M Noordermeer, Salomé Adam, Dheva Setiaputra, et al.
Pageof 3